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Abstract
Background Escalating demands upon the National Institute for Health and Care Excellence’s (NICE’s) Single Technology 
Appraisal (STA) programme require a 2.5-times increase upon 2015 capacity by 2020. This additional strain on commit-
tee resources threatens to compromise the rigour of the STA process. In 2018, NICE introduced changes to the appraisal 
process, aiming to expedite inal decisions, including consultation opportunities prior to the company’s evidence submis-
sion, a ‘Technical Engagement’ stage prior to the irst committee meeting, and powers for committee chairs to recommend 
technologies without a second formal meeting.
Objective This study reviews recent STAs and aims to understand why appraisals require multiple meetings, and whether 
recent reforms can address the underlying issues.
Methods NICE STAs published between January 2010 and January 2018 were reviewed, excluding updates or re-consider-
ations. Data on cost, clinical, and decision-making outcomes from 146 appraisals were extracted and analysed thematically.
Results Drugs for advanced cancers were least likely to be recommended (28/43 [65.1%] vs 71/74 [96%] for non-cancer) and 
took longer (2.36 meetings for a inal decision vs 1.97 for non-cancer). The academic review increased upon the company’s 
base-case incremental cost-efectiveness ratio by a median of 32.7%. Eighty-four technologies (57.5%) received a negative 
preliminary recommendation, deferring a inal decision by an average of 142 days. Of these, 85.1% were not considered 
cost-efective. Uncertainty in economic (34.3%) and clinical (22.3%) data also prevented a positive decision. The major-
ity (72.6% [61/84]) of negative preliminary decisions were overturned following further committee discussion; important 
considerations were Patient Access Schemes, decision optimisation, and the Cancer Drugs Fund.
Conclusions Value considerations are the primary driver of negative preliminary recommendations. It is unclear if new 
opportunities for additional interaction between NICE, review groups, and manufacturers will meaningfully improve the 
eiciency of the appraisal process, particularly given the proportion of technologies requiring further committee discussion 
for decision optimisation or admission into the CDF. 
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supplementary material, which is available to authorized users.
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Key Points for Decision Makers 
National Institute for Health and Care Excellence 
(NICE) has introduced further opportunities for techni-
cal engagement and co-operation with manufacturers 
during the Single Technology Appraisal process to help 
the Appraisal Committee make more timely decisions. 
It remains uncertain if this will have any substantive 
impact on overall process eiciency.
The vast majority of NICE’s negative decisions stem 
from an often wide disparity between manufacturer and 
Evidence Review Group estimates of the value of a new 
technology.
The introduction or enhancement of a Patient Access 
Scheme discount and focus on a more clinically efective 
or cost-efective subgroup were the two most efective 
ways of overturning a negative preliminary decision.
Over half of all cancer drugs have been approved 
through the reformed Cancer Drugs Fund in the 
18 months from January 2017, resulting in a greater 
overall proportion of approvals. However, the time it 
takes to reach a inal decision appears to be increasing.
1 Introduction
The National Institute for Health and Care Excellence’s 
(NICE’s) Single Technology Appraisal (STA) process is the 
principal route via which new pharmacological technologies 
are evaluated for a single indication in the English National 
Health Service (NHS). This constitutes a formal submis-
sion of evidence on the clinical efectiveness and cost-efec-
tiveness of the technology by the manufacturer, which is 
reviewed, critiqued, and supplemented by an independent 
Evidence Review Group (ERG). This evidence is then con-
sidered by a NICE Technology Appraisal Committee, who 
provide a judgement on whether the technology should be 
recommended as an efective use of NHS resources. This 
may take the form of the Appraisal Consultation Document 
(ACD), in which the Appraisal Committee sets out its pro-
visional recommendations, or the Final Appraisal Determi-
nation (FAD), which is issued after the committee’s inal 
decision is made [1].
The technology appraisal programme has in recent 
years seen a rapid increase in demand; it is expected that 
the annual number of appraisals will increase to 75 over 
the next 2 years, from only 30 in 2015 [2]. NICE has sug-
gested several potential reasons for this trend, principally 
the introduction of increasingly tissue-agnostic cancer drugs 
[3], which under current processes may have more than ten 
indications to be individually appraised [2]. Another chal-
lenge is presented by the growing tendency for marketing 
authorisation to be granted earlier in product development. 
While this can mean more timely access for patients, it also 
adds greater complexity and uncertainty to each topic. Given 
the increasing demands placed upon the appraisal commit-
tees, NICE has judged the substantial committee resources 
currently dedicated to each topic to be ineicient and unsus-
tainable [2]. Each appraisal now requires an average of 2.5 
meetings [2] and extensive consultation until a decision 
can be reached and inal guidance produced, meaning an 
increase of 45 topics could require over 100 further com-
mittee meetings.
NICE anticipates that the accommodation of such a 
capacity increase will require fundamental changes to the 
appraisal process. There are currently no plans to increase 
the number of committees or meetings; therefore, as the 
amount of committee time allocated for the discussion of 
each topic decreases, it is possible that these meetings will 
become insuicient to fully consider the case for a decision. 
NICE have noted that while the majority of topics ultimately 
receive positive guidance, it is estimated that 60% of draft 
recommendations are negative [2]; however, the reasons for 
this are not fully resolved.
In recognition of the unsustainable required increases 
in resources and committee and ERG time, in April 2018, 
NICE introduced changes to the STA process aimed at 
reducing the need for multiple committee meetings. This is 
further to the earlier introduction of the Fast Track Appraisal 
process [4], which aimed to reduce time to approval and 
reduce resource use for highly cost-efective technologies 
[< £10,000 per quality-adjusted life year (QALY)] with an 
obvious and signiicant beneit over existing practice. How-
ever, it has been suggested that these changes may not signif-
icantly impact the overall eiciency of the process because 
of the small number of appraisals afected and other unex-
pected complications which often arise during STAs [5].
In these latest changes, NICE highlighted the increas-
ing need for further evidence during consultation following 
provisional recommendations, both at the request of com-
mittees and companies—particularly when considering 
whether to recommend funding a technology through the 
recently reformed Cancer Drugs Fund (CDF). Companies 
are now invited to discuss their evidence submission earlier 
in the regulatory process, and with greater guidance from 
the NICE technical team, who along with the ERG will have 
more engagement in technical and methodological issues 
prior to the primary evidence submission [1]. Processes 
now also allow for a ‘technical engagement’ stage follow-
ing the completion of the ERG report, in which the views of 
clinical, patient, and commissioning experts are sought. This 
ofers an opportunity to address outstanding uncertainty in 
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the evidence submission and to resolve key questions raised 
by the ERG. The company may provide new evidence and 
analysis prior to the irst committee meeting to facilitate 
more focused discussion. NICE also aims to reduce the use 
of a second committee meeting when only commercial con-
siderations have changed. The Committee Chair now has 
the authority to make a inal decision in cases where the 
company provides a suiciently improved commercial ofer 
in response to the ACD [1].
While the factors addressed in these most recent revi-
sions to the STA process may facilitate cooperation between 
stakeholders in an appraisal, these issues may only be a 
symptom of deeper issues in the way manufacturers engage 
with the appraisal process. A greater understanding of the 
underlying causes of negative preliminary decisions, and the 
relationship between disease areas and associated economic 
considerations could inform more targeted reform of STA 
processes, and sustainably and eiciently allow the inevita-
ble increases in appraisal throughput, without compromising 
the rigour of the STA process. This study reviews 8 years 
of previous STAs to better understand why certain topics 
require more meetings and resources to reach a inal deci-
sion, and how far the recent changes to the STA process may 
go to increasing its eiciency and sustainability.
2  Methods
2.1  Appraisal Selection
Researchers from the University of York and the Univer-
sity of Sheield compiled a list of all NICE Technology 
Appraisal guidance for full STAs of any intervention or indi-
cation completed between January 2010 and 31 December 
2017. STA documents (namely the Committee Papers and 
FAD) were independently screened by two authors (MW and 
JOC) against the following eligibility criteria:
1. Must be a full STA.
2. Published between 01/01/2010 and 31/12/2017.
Appraisals were excluded if:
1. They were reconsiderations or updates of previous STAs 
(including CDF rapid reconsiderations).
2. The appraisal had been terminated, e.g. due to failure to 
receive a licence.
3. Guidance had since been withdrawn.
Twenty-seven further appraisals were excluded after 
extraction as important information [typically incremen-
tal cost-efectiveness ratios (ICERs)] had been redacted 
or was otherwise missing from appraisal documents. An 
updated review of NICE’s decisions and use of the CDF 
was performed in August 2018 and included all appraisals 
of cancer drugs published between January and July 2018 
inclusive.
2.2  Data Extraction
Relevant documentation for each appraisal was obtained 
from the NICE website, including the full Committee 
Papers and ERG reports, ACDs, and FADs. Data were 
extracted from these documents by a single reviewer 
(MW) into a standardised data extraction tool based on 
that used by Kaltenthaler and colleagues [6]. The data 
extracted included the following: technology appraisal 
title and number, disease area, appraisal committee, com-
pany and ERG base-case ICERs, appraisal committee–pre-
ferred ICER at ACDs and FAD, recommendations at each 
stage and the reasons behind them, the CDF, and decision 
optimisation (where a recommendation was restricted to 
more cost-efective sub-populations). Information about 
the introduction and progression of Patient Access Scheme 
(PAS) discounts, the number of appraisal committee meet-
ings, and the time from irst committee meeting to the 
FAD were also extracted. All data were independently 
checked for accuracy by a second reviewer (JOC) to ensure 
consistency.
2.3  Analysis
Descriptive summary statistics were generated for each of 
the quantitative items extracted as listed above (e.g. ICERs, 
number of appraisal committee meetings); these were also 
calculated for subgroups such as disease area and committee, 
with mean ICERs by preliminary decision and inal decision 
also calculated. Linear and logistic regression analyses were 
performed to explore relationships between variables, such 
as the disease area, company and ERG base-case ICERs, the 
introduction of PAS discounts, year of appraisal, duration of 
appraisal, and number of committee meetings, and ACD and 
FAD decisions. For some analyses, technologies indicated 
for cancer were further split by whether or not they were 
indicated for cancers described as advanced, metastatic, or 
otherwise classed as ‘end-of-life’. All statistical analyses 
were performed using Stata 15.
A narrative synthesis of the extracted data was performed, 
which highlighted potentially important patterns and rela-
tionships within the dataset.
The factors inluencing the likelihood of a negative pre-
liminary recommendation and the reversal of negative deci-
sions in the FAD were investigated through simple descrip-
tive statistics and logistic regression analysis.
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3  Results
A total of 146 STAs conducted between 1 January 2011 
and 31 December 2017 met the study inclusion criteria. A 
further 24 studies were included following a rapid review of 
decisions on cancer drugs appraised between January and 
July 2018 inclusive. A lowchart of the selection process is 
Fig. 1  PRISMA low diagram of appraisal selection process. PRISMA preferred reporting items for systematic reviews and meta-analyses, STA 
single technology appraisal
Fig. 2  Number of committee 
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presented in Fig. 1. See the Appendix in the electronic sup-
plementary material for a list of the included STAs.
The main disease areas covered by the STA process 
were cancer (72/146, 49.3%), cardiovascular conditions 
(14/146, 9.6%), autoimmune diseases (10/146, 6.8%), and 
eye conditions (9/146, 6.2%). Overall, 123 (84.2%) of STAs 
ended with a positive inal recommendation; however, a 
signiicantly lower proportion (28/43, 65.1%) of drugs for 
advanced or ‘end-of-life’ cancers received a positive inal 
recommendation (χ2 [2, N = 146] = 19.8, p < 0.001). Despite 
making up only 29.5% of included STAs, drugs for advanced 
cancers comprised 65% of all negative recommendations. 
Non-advanced cancer drugs were approved 82.8% of the 
time (24/29), while drugs indicated for conditions other than 
cancer were approved in 96% of cases (71/74). Notably, in 
the 2 years since the relaunch of the CDF, 81.1% of cancer 
drugs appraised have received some form of positive recom-
mendation, compared to 63.3% between 2000 and 2016 [7].
3.1  The Determinants of Multiple Committee 
Meetings
An average of 2.16 (95% conidence interval [CI] 2.01–2.32) 
committee meetings were required to reach a inal decision 
across all disease areas. A inal decision was reached in one 
meeting for only 20.5% of technologies, with the majority 
(54%) requiring two (see Fig. 2). Cancer drugs required the 
most meetings (2.36, 95% CI 2.12–2.60), while drugs for all 
other indications took 1.97 meetings (95% CI 1.79–2.15) to 
reach a inal decision. There were no statistically signiicant 
trends over time in the number of committee meetings dedi-
cated to each appraisal, and no other factors were found to 
be inluential.
In most cases (84/146, 57.5%), the committee issued a 
negative preliminary recommendation following the irst 
committee meeting. The implications of a negative prelimi-
nary decision are signiicant, typically delaying the publica-
tion of inal guidance by a further 142 days. Final guidance 
is published in an average of 98 days (95% CI 86–111) fol-
lowing a positive preliminary recommendation, increasing to 
240 days (95% CI 202–274) after a negative preliminary rec-
ommendation. Cancer drug appraisals took 224 days (95% 
182–266) from the irst committee meeting to publication of 
inal guidance, while this was 148 days (95% CI 120–176) 
across all other disease areas.
The reasons for a negative preliminary decision can be 
grouped into three categories, with some decisions citing all 
three. Most (85.1%, 57/67) technologies were judged not to 
be a cost-efective use of NHS resources using the commit-
tee’s preferred ICER. The committee also often considered 
the uncertainty of the presented cost (34.3%, 23/67) or clini-
cal efectiveness (22.3%, 15/67) too great to make a reliable 
decision and decide upon a preferred set of assumptions, 
citing immature, limited, or inappropriate clinical data 
which had been inadequately analysed or modelled.
The divergence in cost-efectiveness estimates presented 
to the committee by the company and ERG was a signiicant 
factor in many negative preliminary decisions. At the time 
of the irst committee meeting, the mean base-case ICER 
as presented by the manufacturer was £31,635 per QALY 
gained (95% CI 25,947–37,324) across all indications. The 
mean ICER preferred by the ERG was signiicantly higher, 
at £51,644 per QALY gained (95% CI 42,675–60,612). Fol-
lowing the ERG’s review of the company submission, the 
base-case ICER increased by a median of 32.7% (mean 63%) 
on the company’s estimate; this was 41.1% for advanced 
cancer drugs and 22.5% for other types of non-advanced 
cancer. This excludes instances where a judgement of domi-
nance by the company was not agreed with by the ERG, 
which means these igures may overestimate the mean com-
pany base-case ICER and underestimate the increase in the 
ERG preferred ICER.
The magnitude of the diference between the company 
and ERG cost-efectiveness estimates was inluential in 
the preliminary decision; logistic regression analysis indi-
cated that each £1000 diference in the ERG and company 
base cases was associated with a decrease of 0.04 (95% CI 
0.02–0.07) in the odds of a positive preliminary decision, 
Table 1  Mean ICERs of technologies recommended by NICE
CI conidence interval, FAD Final Appraisal Determination, ICER 
incremental cost-efectiveness ratio, NICE National Institute for 
Health and Care Excellence
Disease area No. FAD ICER (£) 95% CI
Total 123 26,431 23,268–29,594
Non-advanced cancer 24 30,784 24,783–36,785
Advanced cancer 28 41,462 35,811–48,112
Other 71 17,075 14,519–19,631
37.7%
32.8%
18.0%
11.5%
Paent Access Scheme
Decision opmisaon
CDF (since July 2016)
New evidence or analysis
N=61
Fig. 3  Primary reason for reversal of a negative preliminary decision. 
CDF cancer drugs fund
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i.e. greater uncertainty in value estimates made a negative 
decision more likely.
Across all indications, NICE approved drugs at £26,431 
per QALY gained on average (95% CI 23,268–29,594). The 
mean ICER at FAD is presented by indication in Table 1. 
There were no apparent trends over time in the ICER at 
which technologies were approved by NICE, and regres-
sion analysis adjusting for committee case mix in terms of 
disease area showed no statistically signiicant diference 
in the ICERs at which the diferent committees approved 
technologies.
Drugs receiving a positive preliminary decision or which 
went straight to a positive FAD were generally priced well 
below their respective willingness-to-pay (WTP) thresholds; 
NICE’s average preferred estimates of cost-efectiveness 
were £17,010 per QALY gained for non-advanced can-
cers, £31,123 for advanced cancers, and £8,653 for other 
indications.
3.2  Reversal of Negative Preliminary Decisions
Out of 84 negative provisional decisions, 61 technologies 
(72.6%) went on to receive a positive inal recommendation 
after further committee discussion. The main reasons for the 
reversal of a negative preliminary ACD recommendation 
are presented in Fig. 3, and comprised the following: the 
introduction or enhancement of a PAS discount (37.7%), 
approval in more clinically efective or cost-efective sub-
groups (32.8%); the decision to fund the drug through the 
CDF, i.e. clinical uncertainty which could reasonably be 
resolved through a period of data collection (18%); and pro-
vision of new clinical evidence or analysis (11.5%).
Technologies indicated for advanced cancers were less 
likely to have a negative preliminary decision reversed 
(odds ratio [OR] 0.19, 95% CI 0.067–0.56), with 17 out of 
32 drugs (53.1%) receiving a negative ACD recommenda-
tion going on to be approved, while this was the case for 15 
out of 20 non-advanced cancer drugs (75%) and 29 out of 
32 drugs for other indications (90%).
PAS discounts are an important means of improving the 
likelihood of a positive recommendation. While inclusion 
of a PAS in the company’s irst evidence submission did 
not afect the likelihood of a positive ACD recommenda-
tion, the introduction or enhancement of a PAS following 
a negative ACD recommendation meant a technology was 
4.32 times more likely (95% CI 1.16–16.15) to receive a 
positive inal recommendation, increasing to an OR of 6.4 
(95% CI 1.57–26.31) in cancer drugs. The introduction of a 
PAS following the ACD was associated with a median 38.7% 
(Interquartile range [IQR] 31.8%, range 0–77.4%) reduction 
in the FAD ICER based on the ERG’s preferred base case 
for recommended technologies.
The FAD ICER was in excess of the committee’s pre-
ferred WTP threshold in 23 out of 24 of the drugs whose 
negative ACD recommendation was not reversed, with 
strength of uncertainty alone responsible for only one nega-
tive recommendation at FAD.
3.3  The Impact of the Cancer Drugs Fund
Following the introduction of the new CDF in 2016, 19 
drugs have been recommended for use within the CDF, a 
mechanism which allows uncertainty around the eicacy of 
a technology to be resolved through a period of data col-
lection. Between 2017 and July 2018, 54% (19/35) of all 
cancer drug recommendations were through the CDF. In 
2017, the mean preferred ICER at FAD for drugs approved 
in advanced cancers was £53,887 (95% CI 46,849–60,925), 
slightly above the increased threshold for technologies meet-
ing NICE’s criteria for life-extending end-of-life therapies 
of £50,000. The mean FAD ICER was £41,810 for all other 
non-advanced cancer drugs funded through the CDF. The 
mean duration of the committee appraisal process for cancer 
drugs increased from 208 days in 2015 to 244 days in 2016, 
and 275 days in 2017.
4  Discussion
Not unexpectedly, the NICE STA process works most ei-
ciently when appraising technologies with well-charac-
terised eicacy proiles, priced well below NICE’s WTP 
thresholds. Unfortunately, the distribution of such technolo-
gies is inequitable across disease areas, with the greater cost 
and uncertainty associated with drugs indicated for cancer 
(particularly advanced forms) leading to slower and more 
commonly negative inal decisions. This review identiied 
the outcome and decision determinants of the irst appraisal 
committee meeting as the best indicator of the obstacles to 
decision making faced by the appraisal committees, and the 
evidence provided in the subsequent consultation documents 
and FAD was used to understand how these were overcome.
The results of this analysis demonstrate that the most con-
sistently cited decision factor in NICE’s negative provisional 
decisions, and therefore the most signiicant barrier to rapid 
decision making is cost-efectiveness; strongly supportive 
of earlier reviews of NICE’s decision-making processes [8, 
9]. This appears to originate from consistent mischaracteri-
sation of a technology’s value and efectiveness by manu-
facturers, leading to uncertainty or doubt surrounding its 
cost-efectiveness following independent academic review.
The issues preventing a positive decision cited in the 
ACDs were satisfactorily resolved in the vast majority of 
cases, principally through decision optimisation and the 
introduction or enhancement of commercial ofers. The 
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recently introduced changes to the STA processes, namely 
the technical engagement step, may facilitate earlier commu-
nication regarding the committee’s requirements and prefer-
ences. If implemented efectively, this could help resolve 
key issues prior to the irst committee meeting and focus 
discussion on the key issues. If the number of negative pre-
liminary decisions could be reduced, a signiicant reduction 
in the time taken to produce inal guidance, and thus patient 
access to treatment, could be achieved.
However, it is unlikely that a resolution to the majority 
of issues raised by the ERG and NICE would be achieved 
through the technical engagement step as currently imple-
mented. As a strategic player, manufacturers are unlikely to 
pre-emptively reduce their price to increase the likelihood 
of an early approval, or re-focus their submission on a more 
cost-efective subgroup. At this stage in the appraisal, there 
is no ‘correct’ cost-efectiveness estimate or set of preferred 
assumptions, and there is no guarantee that the committee 
will favour those proposed by the ERG. Therefore, a com-
pany has little to lose by maintaining their position and 
arguing against the validity of the ERG’s analysis, rather 
than acting against their own interests by way of discounts. 
Furthermore, it is the prerogative of the committee alone to 
make considerations on the equitability of decision optimi-
sation—i.e. placing restrictions upon the access to a drug 
for particular patient groups—and it is natural for compa-
nies to seek to market their product to the entire population 
covered under the licence. Where the committee is minded 
to approve a technology in more cost-efective subgroups, 
or where the suitability of a technology for routine com-
missioning is under consideration (i.e. possible use of the 
CDF), it is highly likely further meetings will be required 
regardless of recent process changes.
In 38% of reversed negative preliminary decisions, the 
basis upon which the committee changed their decision was 
the introduction or enhancement of a PAS discount, which 
suiciently reduced the ICER to below the WTP threshold. 
In these cases, the new powers of committee chairs to rec-
ommend a technology when cost is the only concern may 
yield a substantial reduction in unnecessary meetings.
Historically, technologies indicated for cancers, and 
particularly advanced cancers, have been less successful 
in gaining approval from NICE than those for other indi-
cations. The CDF was reformed in 2016 in an attempt to 
curb the approval of highly cost-inefective treatments in 
light of rapidly escalating costs, which stood at £416 million 
in 2014, an increase of £185 million on the previous year 
[10]. The CDF is now limited to drugs which have plausible 
potential to satisfy the criteria for routine commissioning 
[11], but around which there is signiicant remaining clini-
cal uncertainty, typically due to immature trial data, which 
could be resolved through ongoing data collection. However, 
the application of the concept of ‘plausible potential’ can be 
diicult to determine, particularly where an expensive treat-
ment’s cost-efectiveness relies upon extrapolated long-term 
beneits.
As most negative preliminary recommendations due to 
clinical uncertainty are for cancer drugs, it is likely that the 
reformed CDF will account for a signiicant proportion of 
resolvable clinical uncertainty. Indeed, since its inception, 
the CDF has been used as a vehicle for over half of all can-
cer drug recommendations, and appears to be responsible 
for a marked increase in drug approvals in this period. The 
CDF is a valuable tool for resolving clinical uncertainty, and 
accommodates both the protection of NHS resources from 
potentially inefective products and the timely delivery of 
patient access to new technologies. The increased approval 
rate of drugs earlier in the development cycle is positive for 
UK patients, where drugs have historically been made avail-
able later than in other jurisdictions without Health Technol-
ogy Assessment bodies such as NICE [12, 13]. However, 
this system may provide companies with an incentive to 
withhold evidence to exploit existing clinical uncertainty in 
order to gain access to the NHS and set prices high, despite 
unproven long-term cost-efectiveness.
Unless the technical engagement step can identify when 
evidence is too immature for decision making and advise 
against routine commissioning at an early stage, rather than 
following a negative preliminary recommendation and fur-
ther committee discussion, it is unlikely that this process 
will signiicantly reduce the number of required committee 
meetings. Furthermore, the extent of integration of CDF eli-
gibility assessment with new NICE consultation processes 
is currently unclear, and indeed may not be possible without 
wider restructuring of the appraisal processes. Thus, new 
opportunities for further technical engagement and consulta-
tion prior to appraisal committee discussion are not likely to 
substantially reduce the time to a inal decision for cancer 
drugs.
A number of factors linked to the use of secondary data 
sources may have limited the accuracy of some analyses 
featured in this study. A key limitation was the exclusion 
of dominant ICERs from analyses. Companies often pre-
sented a base case in which their technology dominated 
its competitors, while the ERG’s preferred assumptions 
produced a numerical ICER, which may have led to the 
underestimation of ICER changes. Imprecision in the cost-
efectiveness estimates reported in NICE’s decision docu-
ments was common, with preferred ICERs often presented 
as a range or described as ‘around’ or ‘below’ the WTP 
threshold. Inconsistent reporting across NICE and ERG 
documents may also have led to inappropriately narrow 
conclusions around the reasons for decisions, as full expla-
nations were rarely presented in the ACD or FAD. This 
was particularly the case when one factor overshadowed 
the others, which consequently were not reported.
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5  Conclusions
While it does not appear to be the case that more com-
mittee meetings are becoming necessary for each topic, 
greater uncertainty and complexity around an increasing 
number of topics is placing an ever-greater burden upon 
NICE and its resources. Challenging trends in the imma-
turity of the evidence base around many new technologies 
mean fundamental issues can take many months to resolve, 
often requiring further analysis from the company, the 
ERG, or in some instances, the Decision Support Unit [6]. 
Commercial negotiations between the company and NHS 
England also introduce further delays, particularly when 
there is a large anticipated budget impact. This defers a 
inal decision and ultimately the availability of a new tech-
nology to patients. This is apparent in the increases in 
cancer drug appraisal duration seen here.
The recent changes introduced to the STA protocol 
and new powers of chairs to approve on price will help 
alleviate delays and ineicient use of committee time for 
repetitive cost and commercial discussion. Signiicant 
challenges to eiciency and rigour still remain, including 
uncertainty in value assessment and application of WTP 
thresholds, decision optimisation, commissioning deci-
sions, and perverse incentives promoting obfuscation and 
pricing to thresholds. It is important that committees are 
adequately resourced to enable them to make appropriate, 
informed, and timely decisions, ensuring the NHS contin-
ues to maximise net population health through eicient 
allocation of funds, and ensure patient access to efective 
new technologies.
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